Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): At the cross-road of pancreatic cancer cell proliferation

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 1, 2014, Pages 42-52

  Dicitore, Alessandra ^a   Caraglia, Michele ^b   Gaudenzi, Germano ^c   Manfredi, Gloria ^c   Amato, Bruno ^d   Mari, Daniela ^c,e   Persani, Luca ^a,c   Arra, Claudio ^f   Vitale, Giovanni ^a,c  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

JAK 2 STAT 3 pathway; Pancreatic adenocarcinoma; PPAR ; Type I interferon

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA INTERFERON; CIGLITAZONE; CISPLATIN; CYTOKINE; DECOY OLIGODEOXYNUCLEOTIDE; DOXORUBICIN; EFATUTAZONE; FLUDARABINE; G QUARTET OLIGODEOXYNUCLEOTIDE; GEMCITABINE; INTERFERON; JANUS KINASE 2; LY 171833; OLIGODEOXYNUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RIVOGLITAZONE; ROSIGLITAZONE; STAT3 PROTEIN; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; VIRUS HEPATITIS;

JAK-2/STAT-3 PATHWAY; PANCREATIC ADENOCARCINOMA; PPAR-Γ; TYPE I INTERFERON;

ANIMALS; CELL PROLIFERATION; HUMANS; INTERFERON TYPE I; INTERFERON-BETA; PANCREATIC NEOPLASMS; PPAR GAMMA; SIGNAL TRANSDUCTION;

EID: 84890769381     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.11.003     Document Type: Review

References (165)

1. Anderson K.E., Mack T., Silverman D. Cancer of the Pancreas 2006, Oxford University Press, New York.
2. Sohn T.A., Yeo C.J., Cameron J.L., Koniaris L., Kaushal S., Abrams R.A., Sauter P.K., Coleman J., Hruban R.H., Lillemoe K.D. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg. 2000, 4:567-579.
3. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., Buchler M.W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004, 350:1200-1210.
4. Rahma O.E., Duffy A., Liewehr D.J., Steinberg S.M., Greten T.F. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann. Oncol. 2013, 24:1972-1979.
5. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363:1049-1057.
6. Caraglia M., Dicitore A., Marra M., Castiglioni S., Persani L., Sperlongano P., Tagliaferri P., Abbruzzese A., Vitale G. Type I interferons: ancient peptides with still under-discovered anti-cancer properties. Protein Pept. Lett. 2013, 20:412-423.
7. Dicitore A., Caraglia M., Colao A., Zappavigna S., Mari D., Hofland L.J., Persani L., Vitale G. Combined treatment with PPAR-gamma agonists in pancreatic cancer: a glimmer of hope for cancer therapy?. Curr. Cancer Drug Targets 2013, 13:460-471.
8. Caraglia M., Marra M., Pelaia G., Maselli R., Caputi M., Marsico S.A., Abbruzzese A. Alpha-interferon and its effects on signal transduction pathways. J. Cell. Physiol. 2005, 202:323-335.
9. Gray R.J., Pockaj B.A., Kirkwood J.M. An update on adjuvant interferon for melanoma. Cancer Control 2002, 9:16-21.
10. Tagliaferri P., Caraglia M., Budillon A., Marra M., Vitale G., Viscomi C., Masciari S., Tassone P., Abbruzzese A., Venuta S. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol. Immunother. 2005, 54:1-10.
11. Bromberg J., Darnell J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473.
12. Vitale G., Zappavigna S., Marra M., Dicitore A., Meschini S., Condello M., Arancia G., Castiglioni S., Maroni P., Bendinelli P., Piccoletti R., van Koetsveld P.M., Cavagnini F., Budillon A., Abbruzzese A., Hofland L.J., Caraglia M. The PPAR-gamma agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-beta treated pancreatic cancer cells. Biotechnol. Adv. 2012, 30:169-184.
13. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., Stark G.R. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 2007, 6:975-990.
14. Pestka S. The human interferon alpha species and receptors. Biopolymers 2000, 55:254-287.
15. Jonasch E., Haluska F.G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001, 6:34-55.
16. Domanski P., Colamonici O.R. The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev. 1996, 7:143-151.
17. Domanski P., Witte M., Kellum M., Rubinstein M., Hackett R., Pitha P., Colamonici O.R. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J. Biol. Chem. 1995, 270:21606-21611.
18. Pestka S. The interferon receptors. Semin. Oncol. 1997, 24:S9-18-S19-40.
19. Sadowski H.B., Shuai K., Darnell J.E., Gilman M.Z. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 1993, 261:1739-1744.
20. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202:8-32.
21. Bromberg J. Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res. 2000, 2:86-90.
22. Benekli M., Baer M.R., Baumann H., Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003, 101:2940-2954.
23. Fish E.N., Uddin S., Korkmaz M., Majchrzak B., Druker B.J., Platanias L.C. Activation of a CrkL-stat5 signaling complex by type I interferons. J. Biol. Chem. 1999, 274:571-573.
24. Platanias L.C., Uddin S., Bruno E., Korkmaz M., Ahmad S., Alsayed Y., Van Den Berg D., Druker B.J., Wickrema A., Hoffman R. CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Exp. Hematol. 1999, 27:1315-1321.
25. Platanias L.C. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol. Ther. 2003, 98:129-142.
26. Quintas-Cardama A., Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin. Cancer Res. 2013, 19:1933-1940.
27. Caraglia M., Vitale G., Marra M., Budillon A., Tagliaferri P., Abbruzzese A. Alpha-interferon and its effects on signalling pathways within cells. Curr. Protein Pept. Sci. 2004, 5:475-485.
28. Yang C.H., Murti A., Pfeffer L.M. Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival. J. Biol. Chem. 2005, 280:31530-31536.
29. Yang C.H., Murti A., Pfeffer S.R., Kim J.G., Donner D.B., Pfeffer L.M. Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J. Biol. Chem. 2001, 276:13756-13761.
30. You M., Yu D.H., Feng G.S. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol. 1999, 19:2416-2424.
31. Song M.M., Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J. Biol. Chem. 1998, 273:35056-35062.
32. Cheriyath V., Glaser K.B., Waring J.F., Baz R., Hussein M.A., Borden E.C. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J. Clin. Invest. 2007, 117:3107-3117.
33. Caraglia M., Tagliaferri P., Marra M., Giuberti G., Budillon A., Gennaro E.D., Pepe S., Vitale G., Improta S., Tassone P., Venuta S., Bianco A.R., Abbruzzese A. EGF activates an inducible survival response via the RAS->Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. Cell Death Differ. 2003, 10:218-229.
34. Tagliaferri P., Caraglia M., Muraro R., Pinto A., Budillon A., Zagonel V., Bianco A.R. Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy. Anticancer Drugs 1994, 5:379-393.
35. Budillon A., Di Gennaro E., Caraglia M., Barbarulo D., Abbruzzese A., Tagliaferri P. 8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor. Br. J. Cancer 1999, 81:1134-1141.
36. Caraglia M., Pinto A., Correale P., Zagonel V., Genua G., Leardi A., Pepe S., Bianco A.R., Tagliaferri P. 5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. Ann. Oncol. 1994, 5:269-276.
37. Aikawa R., Komuro I., Yamazaki T., Zou Y., Kudoh S., Tanaka M., Shiojima I., Hiroi Y., Yazaki Y. Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J. Clin. Invest. 1997, 100:1813-1821.
38. von Gise A., Lorenz P., Wellbrock C., Hemmings B., Berberich-Siebelt F., Rapp U.R., Troppmair J. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol. Cell. Biol. 2001, 21:2324-2336.
39. Zhou H., Li X.M., Meinkoth J., Pittman R.N. Akt regulates cell survival and apoptosis at a postmitochondrial level. J. Cell Biol. 2000, 151:483-494.
40. Naviglio S., Spina A., Marra M., Sorrentino A., Chiosi E., Romano M., Improta S., Budillon A., Illiano G., Abbruzzese A., Caraglia M. Adenylate cyclase/cAMP pathway downmodulation counteracts apoptosis induced by IFN-alpha in human epidermoid cancer cells. J. Interferon Cytokine Res. 2007, 27:129-136.
41. Boccellino M., Giuberti G., Quagliuolo L., Marra M., D'Alessandro A.M., Fujita H., Giovane A., Abbruzzese A., Caraglia M. Apoptosis induced by interferon-alpha and antagonized by EGF is regulated by caspase-3-mediated cleavage of gelsolin in human epidermoid cancer cells. J. Cell. Physiol. 2004, 201:71-83.
42. Lamberti A., Longo O., Marra M., Tagliaferri P., Bismuto E., Fiengo A., Viscomi C., Budillon A., Rapp U.R., Wang E., Venuta S., Abbruzzese A., Arcari P., Caraglia M. C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ. 2007, 14:952-962.
43. Sanges C., Scheuermann C., Zahedi R.P., Sickmann A., Lamberti A., Migliaccio N., Baljuls A., Marra M., Zappavigna S., Reinders J., Rapp U., Abbruzzese A., Caraglia M., Arcari P. Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells. Cell Death Dis. 2012, 3:e276.
44. Schmidt M.V., Brune B., von Knethen A. The nuclear hormone receptor PPARgamma as a therapeutic target in major diseases. ScientificWorldJournal 2010, 10:2181-2197.
45. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S., Vidal-Puig A., Flier J., Briggs M.R., Staels B., Vidal H., Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 1997, 272:18779-18789.
46. Standiford T.J., Keshamouni V.G., Reddy R.C. Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc. Am. Thorac. Soc. 2005, 2:226-231.
47. Heaney A.P. Novel pituitary ligands: peroxisome proliferator activating receptor-gamma. Pituitary 2003, 6:153-159.
48. Kato M., Kusumi T., Tsuchida S., Tanaka M., Sasaki M., Kudo H. Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone. J. Cancer Res. Clin. Oncol. 2004, 130:73-79.
49. Kristiansen G., Jacob J., Buckendahl A.C., Grutzmann R., Alldinger I., Sipos B., Kloppel G., Bahra M., Langrehr J.M., Neuhaus P., Dietel M., Pilarsky C. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin. Cancer Res. 2006, 12:6444-6451.
50. Kubota T., Koshizuka K., Williamson E.A., Asou H., Said J.W., Holden S., Miyoshi I., Koeffler H.P. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998, 58:3344-3352.
51. Ohta K., Endo T., Haraguchi K., Hershman J.M., Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2001, 86:2170-2177.
52. Yin F., Wakino S., Liu Z., Kim S., Hsueh W.A., Collins A.R., Van Herle A.J., Law R.E. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem. Biophys. Res. Commun. 2001, 286:916-922.
53. Rosewicz S., Stier U., Brembeck F., Kaiser A., Papadimitriou C.A., Berdel W.E., Wiedenmann B., Riecken E.O. Retinoids: effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines. Gastroenterology 1995, 109:1646-1660.
54. Rosewicz S., Wollbergs K., Von Lampe B., Matthes H., Kaiser A., Riecken E.O. Retinoids inhibit adhesion to laminin in human pancreatic carcinoma cells via the alpha 6 beta 1-integrin receptor. Gastroenterology 1997, 112:532-542.
55. Laudet V., Hanni C., Coll J., Catzeflis F., Stehelin D. Evolution of the nuclear receptor gene superfamily. EMBO J. 1992, 11:1003-1013.
56. Markt P., Schuster D., Kirchmair J., Laggner C., Langer T. Pharmacophore modeling and parallel screening for PPAR ligands. J. Comput. Aided Mol. Des. 2007, 21:575-590.
57. Izumi T., Hosiyama K., Enomoto S., Sasahara K., Sugiyama Y. Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data. J. Pharmacol. Exp. Ther. 1997, 280:1392-1400.
58. Yu C., Chen L., Luo H., Chen J., Cheng F., Gui C., Zhang R., Shen J., Chen K., Jiang H., Shen X. Binding analyses between human PPARgamma-LBD and ligands. Eur. J. Biochem. 2004, 271:386-397.
59. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., Evans R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992, 358:771-774.
60. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
61. Gelman L., Fruchart J.C., Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell. Mol. Life Sci. 1999, 55:932-943.
62. Puigserver P., Adelmant G., Wu Z., Fan M., Xu J., O'Malley B., Spiegelman B.M. Activation of PPARgamma coactivator-1 through transcription factor docking. Science 1999, 286:1368-1371.
63. Zhu Y., Qi C., Calandra C., Rao M.S., Reddy J.K. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. Gene Expr. 1996, 6:185-195.
64. Glass C.K., Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat. Rev. Immunol. 2006, 6:44-55.
65. Pascual G., Glass C.K. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. 2006, 17:321-327.
66. Ricote M., Glass C.K. PPARs and molecular mechanisms of transrepression. Biochim. Biophys. Acta 2007, 1771:926-935.
67. Grommes C., Landreth G.E., Heneka M.T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004, 5:419-429.
68. Dowell P., Ishmael J.E., Avram D., Peterson V.J., Nevrivy D.J., Leid M. Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. J. Biol. Chem. 1999, 274:15901-15907.
69. Jepsen K., Hermanson O., Onami T.M., Gleiberman A.S., Lunyak V., McEvilly R.J., Kurokawa R., Kumar V., Liu F., Seto E., Hedrick S.M., Mandel G., Glass C.K., Rose D.W., Rosenfeld M.G. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 2000, 102:753-763.
70. Castrillo A., Diaz-Guerra M.J., Hortelano S., Martin-Sanz P., Bosca L. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages. Mol. Cell. Biol. 2000, 20:1692-1698.
71. Park E.J., Park S.Y., Joe E.H., Jou I. 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J. Biol. Chem. 2003, 278:14747-14752.
72. Wei S., Yang J., Lee S.L., Kulp S.K., Chen C.S. PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett. 2009, 276:119-124.
73. Burgermeister E., Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 2007, 6:1539-1548.
74. Xu B., Stippec S., Robinson F.L., Cobb M.H. Hydrophobic as well as charged residues in both MEK1 and ERK2 are important for their proper docking. J. Biol. Chem. 2001, 276:26509-26515.
75. Petryshyn R., Chen J.J., London I.M. Growth-related expression of a double-stranded RNA-dependent protein kinase in 3T3 cells. J. Biol. Chem. 1984, 259:14736-14742.
76. Meurs E.F., Galabru J., Barber G.N., Katze M.G., Hovanessian A.G. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:232-236.
77. Gil J., Esteban M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis 2000, 5:107-114.
78. Murphy D., Detjen K.M., Welzel M., Wiedenmann B., Rosewicz S. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001, 33:346-356.
79. Nikolaeva T.G., Timofeev I.V., Dobrynin Ia V. Effect of interferon on cell cycle phases in cultured human tumor cells. Eksp. Onkol. 1984, 6:52-55.
80. Qin X.Q., Runkel L., Deck C., DeDios C., Barsoum J. Interferon-beta induces S phase accumulation selectively in human transformed cells. J. Interferon Cytokine Res. 1997, 17:355-367.
81. Yano H., Iemura A., Haramaki M., Ogasawara S., Takayama A., Akiba J., Kojiro M. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999, 29:1708-1717.
82. Buechner S.A., Wernli M., Harr T., Hahn S., Itin P., Erb P. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J. Clin. Invest. 1997, 100:2691-2696.
83. Chawla-Sarkar M., Leaman D.W., Borden E.C. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin. Cancer Res. 2001, 7:1821-1831.
84. Chen Q., Gong B., Mahmoud-Ahmed A.S., Zhou A., Hsi E.D., Hussein M., Almasan A. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 2001, 98:2183-2192.
85. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 1999, 189:1451-1460.
86. Selleri C., Sato T., Del Vecchio L., Luciano L., Barrett A.J., Rotoli B., Young N.S., Maciejewski J.P. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 1997, 89:957-964.
87. Spets H., Georgii-Hemming P., Siljason J., Nilsson K., Jernberg-Wiklund H. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood 1998, 92:2914-2923.
88. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., Borden E.C. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8:237-249.
89. Minami R., Muta K., Ilseung C., Abe Y., Nishimura J., Nawata H. Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-alpha. Exp. Hematol. 2000, 28:244-255.
90. Thyrell L., Erickson S., Zhivotovsky B., Pokrovskaja K., Sangfelt O., Castro J., Einhorn S., Grander D. Mechanisms of interferon-alpha induced apoptosis in malignant cells. Oncogene 2002, 21:1251-1262.
91. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N., Trapani J., Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 1998, 161:1947-1953.
92. Raefsky E.L., Platanias L.C., Zoumbos N.C., Young N.S. Studies of interferon as a regulator of hematopoietic cell proliferation. J. Immunol. 1985, 135:2507-2512.
93. Carrero J.A., Calderon B., Unanue E.R. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J. Exp. Med. 2004, 200:535-540.
94. Pilling D., Akbar A.N., Girdlestone J., Orteu C.H., Borthwick N.J., Amft N., Scheel-Toellner D., Buckley C.D., Salmon M. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. Eur. J. Immunol. 1999, 29:1041-1050.
95. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470.
96. Foster G.R., Masri S.H., David R., Jones M., Datta A., Lombardi G., Runkell L., de Dios C., Sizing I., James M.J., Marelli-Berg F.M. IFN-alpha subtypes differentially affect human T cell motility. J. Immunol. 2004, 173:1663-1670.
97. Badr G., Borhis G., Treton D., Richard Y. IFN{alpha} enhances human B-cell chemotaxis by modulating ligand-induced chemokine receptor signaling and internalization. Int. Immunol. 2005, 17:459-467.
98. Curtsinger J.M., Valenzuela J.O., Agarwal P., Lins D., Mescher M.F. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 2005, 174:4465-4469.
99. Herberman R.R., Ortaldo J.R., Bonnard G.D. Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 1979, 277:221-223.
100. Lee C.K., Rao D.T., Gertner R., Gimeno R., Frey A.B., Levy D.E. Distinct requirements for IFNs and STAT1 in NK cell function. J. Immunol. 2000, 165:3571-3577.
101. Zhu Y., Tibensky I., Schmidt J., Hackert T., Ryschich E., Jager D., Buchler M.W., Marten A. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. J. Immunother. 2008, 31:28-33.
102. Konig J., Hartel M., Nies A.T., Martignoni M.E., Guo J., Buchler M.W., Friess H., Keppler D. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer 2005, 115:359-367.
103. Lu Z., Kleeff J., Shrikhande S., Zimmermann T., Korc M., Friess H., Buchler M.W. Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas 2000, 21:240-247.
104. Hoffmann K., Mehrle S., Schmidt J., Buchler M.W., Marten A. Interferon-alpha restitutes the chemosensitivity in pancreatic cancer. Anticancer Res. 2008, 28:1499-1507.
105. Hruban R.H., Goggins M., Parsons J., Kern S.E. Progression model for pancreatic cancer. Clin. Cancer Res. 2000, 6:2969-2972.
106. Chen Z.H., Zhang H., Savarese T.M. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res. 1996, 56:1083-1090.
107. Vitale G., van Eijck C.H., van Koetsveld Ing P.M., Erdmann J.I., Speel E.J., van der Wansem Ing K., Mooij D.M., Colao A., Lombardi G., Croze E., Lamberts S.W., Hofland L.J. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann. Surg. 2007, 246:259-268.
108. Picozzi V.J., Kozarek R.A., Traverso L.W. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am. J. Surg. 2003, 185:476-480.
109. GITSG Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987, 59:2006-2010.
110. Marten A., Schmidt J., Ose J., Harig S., Abel U., Munter M.W., Jager D., Friess H., Mayerle J., Adler G., Seufferlein T., Gress T., Schmid R., Buchler M.W. A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival-CapRI-2. BMC Cancer 2009, 9:160.
111. Pelzer U., Kubica K., Stieler J., Schwaner I., Heil G., Görner M., Mölle M., Hilbig A., Dörken B., Riess H., Oettle H. A randomized trial in patients with gemcitabine-refractory pancreas cancer: final results of the CONKO 003 study. (Abstract). J. Clin. Oncol. 2008, 26.
112. Picozzi V.J., Abrams R.A., Decker P.A., Traverso W., O'Reilly E.M., Greeno E., Martin R.C., Wilfong L.S., Rothenberg M.L., Posner M.C., Pisters P.W. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann. Oncol. 2011, 22:348-354.
113. Schmidt J., Abel U., Debus J., Harig S., Hoffmann K., Herrmann T., Bartsch D., Klein J., Mansmann U., Jager D., Capussotti L., Kunz R., Buchler M.W. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J. Clin. Oncol. 2012, 30:4077-4083.
114. Schmidt J., Jager D., Hoffmann K., Buchler M.W., Marten A. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. J. Immunother. 2007, 30:108-115.
115. Vitale G., de Herder W.W., van Koetsveld P.M., Waaijers M., Schoordijk W., Croze E., Colao A., Lamberts S.W., Hofland L.J. IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res. 2006, 66:554-562.
116. van Koetsveld P.M., Vitale G., de Herder W.W., Feelders R.A., van der Wansem K., Waaijers M., van Eijck C.H., Speel E.J., Croze E., van der Lely A.J., Lamberts S.W., Hofland L.J. Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J. Clin. Endocrinol. Metab. 2006, 91:4537-4543.
117. Wang B., Xiong Q., Shi Q., Le X., Abbruzzese J.L., Xie K. Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. Cancer Res. 2001, 61:71-75.
118. Karpusas M., Nolte M., Benton C.B., Meier W., Lipscomb W.N., Goelz S. The crystal structure of human interferon beta at 2.2-A resolution. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:11813-11818.
119. Johns T.G., Mackay I.R., Callister K.A., Hertzog P.J., Devenish R.J., Linnane A.W. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J. Natl. Cancer Inst. 1992, 84:1185-1190.
120. Croze E., Russell-Harde D., Wagner T.C., Pu H., Pfeffer L.M., Perez H.D. The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein. J. Biol. Chem. 1996, 271:33165-33168.
121. van Koetsveld P.M., Vitale G., Feelders R.A., Waaijers M., Sprij-Mooij D.M., de Krijger R.R., Speel E.J., Hofland J., Lamberts S.W., de Herder W.W., Hofland L.J. Interferon-beta is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Endocr. Relat. Cancer 2013, 20:443-454.
122. Endou M., Mizuno M., Nagata T., Tsukada K., Nakahara N., Tsuno T., Osawa H., Kuno T., Fujita M., Hatano M., Yoshida J. Growth inhibition of human pancreatic cancer cells by human interferon-beta gene combined with gemcitabine. Int. J. Mol. Med. 2005, 15:277-283.
123. Tomimaru Y., Eguchi H., Wada H., Tomokuni A., Kobayashi S., Marubashi S., Takeda Y., Tanemura M., Umeshita K., Mori M., Doki Y., Nagano H. Synergistic antitumor effect of interferon-ss with gemcitabine in interferon-alpha-non-responsive pancreatic cancer cells. Int. J. Oncol. 2011, 38:1237-1243.
124. Morak M.J., van Koetsveld P.M., Kanaar R., Hofland L.J., van Eijck C.H. Type I interferons as radiosensitisers for pancreatic cancer. Eur. J. Cancer 2011, 47:1938-1945.
125. Busch M., Wilkowski R., Schaffer M., Duhmke E. Combined chemotherapy, radiotherapy, and immunotherapy for pancreatic carcinoma-a case report. Adv. Ther. 2000, 17:133-139.
126. Picard F., Auwerx J. PPAR(gamma) and glucose homeostasis. Annu. Rev. Nutr. 2002, 22:167-197.
127. Wang Y.L., Miao Q. To live or to die: prosurvival activity of PPARgamma in Cancers. PPAR Res. 2008, 2008:209629.
128. Krishnan A., Nair S.A., Pillai M.R. Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr. Mol. Med. 2007, 7:532-540.
129. Kawa S., Nikaido T., Unno H., Usuda N., Nakayama K., Kiyosawa K. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas 2002, 24:1-7.
130. Ptak-Belowska A., Pawlik M.W., Krzysiek-Maczka G., Brzozowski T., Pawlik W.W. Transcriptional upregulation of gastrin in response to peroxisome proliferator-activated receptor gamma agonist triggers cell survival pathways. J. Physiol. Pharmacol. 2007, 58:793-801.
131. Jutooru I., Chadalapaka G., Chintharlapalli S., Papineni S., Safe S. Induction of apoptosis and nonsteroidal anti-inflammatory drug-activated gene 1 in pancreatic cancer cells by a glycyrrhetinic acid derivative. Mol. Carcinog. 2009, 48:692-702.
132. Hong J., Samudio I., Liu S., Abdelrahim M., Safe S. Peroxisome proliferator-activated receptor gamma-dependent activation of p21 in Panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins. Endocrinology 2004, 145:5774-5785.
133. Hashimoto K., Farrow B.J., Evers B.M. Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2. Pancreas 2004, 28:153-159.
134. Farrow B., Evers B.M. Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2003, 301:50-53.
135. Yan J., Yang H., Wang G., Sun L., Zhou Y., Guo Y., Xi Z., Jiang X. Autophagy augmented by troglitazone is independent of EGFR transactivation and correlated with AMP-activated protein kinase signaling. Autophagy 2010, 6:67-73.
136. Zhou J., Zhang W., Liang B., Casimiro M.C., Whitaker-Menezes D., Wang M., Lisanti M.P., Lanza-Jacoby S., Pestell R.G., Wang C. PPARgamma activation induces autophagy in breast cancer cells. Int. J. Biochem. Cell Biol. 2009, 41:2334-2342.
137. Jung C.H., Ro S.H., Cao J., Otto N.M., Kim D.H. mTOR regulation of autophagy. FEBS Lett. 2010, 584:1287-1295.
138. Cruz F.D., Matushansky I. Solid tumor differentiation therapy-is it possible?. Oncotarget 2012, 3:559-567.
139. Sawai H., Liu J., Reber H.A., Hines O.J., Eibl G. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol. Cancer Res. 2006, 4:159-167.
140. Xin X., Yang S., Kowalski J., Gerritsen M.E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 1999, 274:9116-9121.
141. Panigrahy D., Singer S., Shen L.Q., Butterfield C.E., Freedman D.A., Chen E.J., Moses M.A., Kilroy S., Duensing S., Fletcher C., Fletcher J.A., Hlatky L., Hahnfeldt P., Folkman J., Kaipainen A. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 2002, 110:923-932.
142. Sabatino L., Fucci A., Pancione M., Colantuoni V. PPARG epigenetic deregulation and its role in colorectal tumorigenesis. PPAR Res. 2012, 2012:687492.
143. Pazienza V., Tavano F., Benegiamo G., Vinciguerra M., Burbaci F.P., Copetti M., di Mola F.F., Andriulli A., di Sebastiano P. Correlations among PPARgamma, DNMT1, and DNMT3B expression levels and pancreatic cancer. PPAR Res. 2012, 2012:461784.
144. Tsujie M., Nakamori S., Okami J., Takahashi Y., Hayashi N., Nagano H., Dono K., Umeshita K., Sakon M., Monden M. Growth inhibition of pancreatic cancer cells through activation of peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Int. J. Oncol. 2003, 23:325-331.
145. Ceni E., Mello T., Tarocchi M., Crabb D.W., Caldini A., Invernizzi P., Surrenti C., Milani S., Galli A. Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. World J. Gastroenterol. 2005, 11:1122-1130.
146. Galli A., Ceni E., Crabb D.W., Mello T., Salzano R., Grappone C., Milani S., Surrenti E., Surrenti C., Casini A. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut 2004, 53:1688-1697.
147. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 1999, 274:32048-32054.
148. Han C., Demetris A.J., Liu Y., Shelhamer J.H., Wu T. Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-beta-induced mitoinhibition. J. Biol. Chem. 2004, 279:44344-44354.
149. Takeuchi Y., Takahashi M., Sakano K., Mutoh M., Niho N., Yamamoto M., Sato H., Sugimura T., Wakabayashi K. Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma. Carcinogenesis 2007, 28:1692-1696.
150. Dong Y.W., Wang X.P., Wu K. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J. Gastroenterol. 2009, 15:441-448.
151. Stephanou A., Latchman D.S. STAT-1: a novel regulator of apoptosis. Int. J. Exp. Pathol. 2003, 84:239-244.
152. Pensa S., Regis G., Boselli D., Novelli F., Poli V. STAT1 and STAT3 in tumorigenesis: two sides of the same coin?. JAK-STAT Pathway in Disease, Landes Bioscience 2009, 100-121. Available from: http://www.ncbi.nlm.nih.gov/books/NBK6568/. A. Stephanou (Ed.).
153. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Kloppel G., Yoshimura A., Reindl W., Sipos B., Akira S., Schmid R.M., Algul H. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
154. Scholz A., Heinze S., Detjen K.M., Peters M., Welzel M., Hauff P., Schirner M., Wiedenmann B., Rosewicz S. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 2003, 125:891-905.
155. Shen Y., Devgan G., Darnell J.E., Bromberg J.F. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1543-1548.
156. Shim S.H., Sung M.W., Park S.W., Heo D.S. Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines. Int. J. Mol. Med. 2009, 23:805-810.
157. Garcea G., Neal C.P., Pattenden C.J., Steward W.P., Berry D.P. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur. J. Cancer 2005, 41:2213-2236.
158. Caraglia M., Marra M., Tagliaferri P., Lamberts S.W., Zappavigna S., Misso G., Cavagnini F., Facchini G., Abbruzzese A., Hofland L.J., Vitale G. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr. Cancer Drug Targets 2009, 9:690-704.
159. Colomiere M., Findlay J., Ackland L., Ahmed N. Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin. Int. J. Biochem. Cell Biol. 2009, 41:1034-1045.
160. Wang L.H., Yang X.Y., Zhang X., Farrar W.L. Nuclear receptors as negative modulators of STAT3 in multiple myeloma. Cell Cycle 2005, 4:242-245.
161. Wang W.M., Zhang H.D., Jin Y.M., Zhu B.B., Chen N. PPAR-gamma agonists inhibit TGF-beta1-induced chemokine expression in human tubular epithelial cells. Acta Pharmacol. Sin. 2009, 30:107-112.
162. Caraglia M., Leardi A., Corradino S., Ciardiello F., Budillon A., Guarrasi R., Bianco A.R., Tagliaferri P. Alpha-Interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. Int. J. Cancer 1995, 61:342-347.
163. Caraglia M., Marra M., Viscomi C., D'Alessandro A.M., Budillon A., Meo G., Arra C., Barbieri A., Rapp U.R., Baldi A., Tassone P., Venuta S., Abbruzzese A., Tagliaferri P. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways. Int. J. Cancer 2007, 121:2317-2330.
164. Gingras A.C., Kennedy S.G., O'Leary M.A., Sonenberg N., Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 1998, 12:502-513.
165. Fagard R., Metelev V., Souissi I., Baran-Marszak F. STAT3 inhibitors for cancer therapy: have all roads been explored?. JAKSTAT 2013, 2:e22882.